## 5 Conclusions  
As a whole, our results indicate that the crude acetone extract of _S. triloba_ posesses anti-proliferative and migratory effects against U2 OS and SKOV3 cells, which respectively represent models of osteosarcoma and ovarian carcinoma. These anti-oncogenic effects could be further potentiated by the extract's ability to modulate the steady-state mRNA expression of key targets, such as RUNX2, that promote the progression of both bone and ovarian cancers. Furthermore, co-administering _S. triloba_ with paclitaxel may permit appropriate dose reduction of paclitaxel, while potentially alleviating chemotherapy induced hemolysis. The potent biological activity of the extract could be owed to their phenolic, terpenoid, flavonoid, and polysaccharide contents as suggested by the FTIR measurementsalong with previous literature reports. To fully elucidate the structure-activity relationships, we recommend further chemical profiling and identification of the bioactive constituents of _S. triloba_ extracts, in addition to testing their activity in vivo. The following supporting information can be downloaded at: [[https://www.mdpi.com/article/10.3390/app122211545/s1](https://www.mdpi.com/article/10.3390/app122211545/s1)]([https://www.mdpi.com/article/10.3390/app122211545/s1](https://www.mdpi.com/article/10.3390/app122211545/s1)), Table S1: Summary of _S. triloba_ acetone extract IC\({}_{50}\) values in U2 OS and SKOV3 cells; Table S2: IC\({}_{50}\) of treatments on Hek-293 cell viability; Table S3: Summary of U2 OS and SKOV3 selectivity index values; Table S4: qPCR primer sequences; Figure S1: Effect of _S. triloba_ ethanol extract on U2 OS cell viability. (A) The _S. triloba_ ethanol extract exhibited negligible effect on U2 OS cell viability after 48 h exposure. (B) U2 OS cell viability was significantly reduced by more than 50% after incubation with cisplatin (48 h) at all examined concentrations; cisplatin served as a positive control for U2 OS cells. Figure S2: Effect of _S. triloba_ ethanol extract on HepG2 cell viability and morphology; Figure S3: DMSO solvent does not affect U2 OS and SKOV3 cell viability; Figure S4: Hek-293 dose-response curves (A) Dose response curve for _S. triloba_ acetone extract on Hek293 cells. The percentage viability was normalized to a scale from 0 to 150 and _S. triloba_ IC\({}_{50}\) value was 75.8 \(\pm\) 1.060. (B) Dose-response curve of paclitaxel on Hek-293 cells. The percentage viability was normalized to a scale from 0 to 150 and paclitaxel IC\({}_{50}\) value was 4.142 \(\pm\) 1.132 ug/mL. (C) Dose-response curve of cisplatin on Hek-293 cells The percentage viability was normalized to a scale from 0 to 150 and cisplatin IC\({}_{50}\) value was 1.69 \(\pm\) 0.868 ug/mL; File S1: CompySyn report. Conceptualization, A.A.; formal analysis, N.A.M.S., R.B.E.-d.A.E.-b., E.Z.M., H.L.E., M.M.H.E.-S., M.S.S., H.F.E., M.A.A.W., R.A. and A.A.; funding acquisition, N.A.M.S., R.B.E.-d.A.E.-b., E.Z.M., M.S.S., H.F.E., M.A.A.W. and A.A.; investigation, N.A.M.S., R.B.E.-d.A.E.-b., E.Z.M., H.L.E., M.M.H.E.-S., M.S.S., H.F.E. and M.A.A.W. ; methodology, N.A.M.S., R.B.E.-d.A.E.-b., E.Z.M., H.L.E., M.M.H.E.-S., M.S.S., H.F.E., M.A.A.W., R.A. and A.A.; project administration, A.A.; resources, R.A. and A.A.; supervision, A.A.; validation, N.A.M.S., R.B.E.-d.A.E.-b., E.Z.M., H.E., M.M.H.E.-S., H.F.E., M.A.A.W., R.A. and A.A.; visualization, N.A.M.S., R.B.E.-d.A.E.-b., E.Z.M., H.L.E., M.M.H.E.-S., M.S.S., H.F.E. and M.A.A.W. ; writing--original draft, N.A.M.S., R.B.E.-d.A.E.-b. and E.Z.M. ; writing--review and editing, N.A.M.S., R.B.E.-d.A.E.-b., E.Z.M., H.L.E., M.M.H.E.-S., M.S.S., H.F.E., M.A.A.W., R.A. and A.A. All authors have read and agreed to the published version of the manuscript. This research was funded by Bartlett Foundation Fund for Critical Challenges Grant (grant no. SSE-Bio-A.A-FY19-FY20) for AA and Student Research Grants for N.A.M.S., R.B.E.-d.A.E.-b., M.S.S., H.F.E. and M.A.A.W. from The American University in Cairo.